دورية أكاديمية
A genomic-augmented multivariate prognostic model for the survival of natural-killer/T-cell lymphoma patients from an international cohort.
| العنوان: | A genomic-augmented multivariate prognostic model for the survival of natural-killer/T-cell lymphoma patients from an international cohort. |
|---|---|
| المؤلفون: | Lim JQ; State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.; Lymphoma Genomic Translational Research Laboratory, Cellular and Molecular Research, National Cancer Centre Singapore, Singapore.; ONCO-ACP, Duke-NUS Medical School, Singapore., Huang D; Lymphoma Genomic Translational Research Laboratory, Cellular and Molecular Research, National Cancer Centre Singapore, Singapore.; ONCO-ACP, Duke-NUS Medical School, Singapore., Chan JY; Division of Medical Oncology, National Cancer Centre Singapore, Singapore., Laurensia Y; Lymphoma Genomic Translational Research Laboratory, Cellular and Molecular Research, National Cancer Centre Singapore, Singapore., Wong EKY; Lymphoma Genomic Translational Research Laboratory, Cellular and Molecular Research, National Cancer Centre Singapore, Singapore., Cheah DMZ; Lymphoma Genomic Translational Research Laboratory, Cellular and Molecular Research, National Cancer Centre Singapore, Singapore., Chia BKH; Lymphoma Genomic Translational Research Laboratory, Cellular and Molecular Research, National Cancer Centre Singapore, Singapore., Chuang WY; Department of Anatomic Pathology, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan.; Chang Gung University, Taoyuan, Taiwan., Kuo MC; Chang Gung University, Taoyuan, Taiwan.; Division of Hematology-Oncology, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan., Su YJ; Division of Hematology-Oncology, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan., Cai QQ; State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.; Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China., Feng Y; State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China., Rao H; State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China., Feng LN; State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China., Wei PP; State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China., Chen JR; State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China., Han BW; State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China., Lin GW; State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China., Cai J; State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China., Fang Y; State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China., Tan J; State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.; Lymphoma Genomic Translational Research Laboratory, Cellular and Molecular Research, National Cancer Centre Singapore, Singapore.; Laboratory of Cancer Epigenome, Division of Medical Sciences, National Cancer Centre Singapore, Singapore., Hong H; State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.; Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China., Liu Y; Guangdong Provincial People's Hospital, Guangdong, China.; Guangdong Academy of Medical Sciences, Guangdong, China., Zhang F; Guangdong Provincial People's Hospital, Guangdong, China.; Guangdong Academy of Medical Sciences, Guangdong, China., Li W; Guangdong Provincial People's Hospital, Guangdong, China.; Guangdong Academy of Medical Sciences, Guangdong, China., Poon MLM; Department of Haematology-Oncology, National University Cancer Institute of Singapore, National University Health System, Singapore., Ng SB; Department of Pathology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore City, Singapore.; Cancer Science Institute of Singapore, National University of Singapore, Singapore City, Singapore., Jeyasekharan A; Cancer Science Institute of Singapore, National University of Singapore, Singapore City, Singapore.; Department of Haematology-Oncology, National University Health System, Singapore City, Singapore., Ha JCH; Lymphoma Genomic Translational Research Laboratory, Division of Medical Oncology, National Cancer Centre Singapore, Singapore City, Singapore., Khoo LP; Lymphoma Genomic Translational Research Laboratory, Division of Medical Oncology, National Cancer Centre Singapore, Singapore City, Singapore., Chin ST; Lymphoma Genomic Translational Research Laboratory, Division of Medical Oncology, National Cancer Centre Singapore, Singapore City, Singapore., Pang WL; Lymphoma Genomic Translational Research Laboratory, Cellular and Molecular Research, National Cancer Centre Singapore, Singapore., Kee R; Lymphoma Genomic Translational Research Laboratory, Division of Medical Oncology, National Cancer Centre Singapore, Singapore City, Singapore., Cheng CL; Department of Pathology, Singapore General Hospital, Singapore City, Singapore., Grigoropoulos NF; Department of Haematology, Singapore General Hospital, Singapore City, Singapore., Tang T; ONCO-ACP, Duke-NUS Medical School, Singapore., Tao M; Division of Medical Oncology, National Cancer Centre Singapore, Singapore., Farid M; Division of Medical Oncology, National Cancer Centre Singapore, Singapore., Puan KJ; Singapore Immunology Network (SIgN), A*STAR (Agency for Science, Technology and Research), Singapore City, Singapore., Xiong J; Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics,National Research Center for Translational Medicine at Shanghai Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China., Zhao WL; Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics,National Research Center for Translational Medicine at Shanghai Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China., Khor CC; Genome Institute of Singapore, Singapore City, Singapore., Hwang W; Director's office, National Cancer Centre, Singapore City, Singapore., Kim WS; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea., Campo E; Institut D'Investigacions Biomediques August Pi I Sunyer, Hospital Clinic, University of Barcelona, Barcelona, Spain., Tan P; Cancer Science Institute of Singapore, National University of Singapore, Singapore City, Singapore.; Genome Institute of Singapore, Singapore City, Singapore.; Programme in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore City, Singapore., Teh BT; Laboratory of Cancer Epigenome, Division of Medical Sciences, National Cancer Centre Singapore, Singapore.; Cancer Science Institute of Singapore, National University of Singapore, Singapore City, Singapore.; Programme in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore City, Singapore., Chng WJ; Department of Haematology-Oncology, National University Cancer Institute of Singapore, National University Health System, Singapore.; Cancer Science Institute of Singapore, National University of Singapore, Singapore City, Singapore., Rötzschke O; Singapore Immunology Network (SIgN), A*STAR (Agency for Science, Technology and Research), Singapore City, Singapore., Tousseyn T; Translational Cell and Tissue Research Lab, Department of Imaging and Pathology, KU Leuven, Leuven, Belgium.; Department of Pathology, UZ Leuven, Leuven, Belgium., Huang HQ; State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China., Rozen S; Programme in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore City, Singapore.; Centre for Computational Biology, Duke-NUS Medical School, Singapore City, Singapore., Lim ST; Director's office, National Cancer Centre, Singapore City, Singapore.; Office of Education, Duke-NUS Medical School, Singapore City, Singapore., Shih LY; Chang Gung University, Taoyuan, Taiwan.; Division of Hematology-Oncology, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan., Bei JX; State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China., Ong CK; Lymphoma Genomic Translational Research Laboratory, Cellular and Molecular Research, National Cancer Centre Singapore, Singapore.; Genome Institute of Singapore, Singapore City, Singapore.; Cancer and Stem Cell Biology, Duke-NUS Graduate Medical School, Singapore City, Singapore. |
| المصدر: | American journal of hematology [Am J Hematol] 2022 Sep; Vol. 97 (9), pp. 1159-1169. Date of Electronic Publication: 2022 Jul 05. |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Wiley-Blackwell Country of Publication: United States NLM ID: 7610369 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1096-8652 (Electronic) Linking ISSN: 03618609 NLM ISO Abbreviation: Am J Hematol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: New York Ny : Wiley-Blackwell Original Publication: New York, Liss. |
| مواضيع طبية MeSH: | Epstein-Barr Virus Infections* , Lymphoma, Extranodal NK-T-Cell*, Disease-Free Survival ; Genomics ; Herpesvirus 4, Human ; Humans ; Prognosis ; Retrospective Studies |
| مستخلص: | With lowering costs of sequencing and genetic profiling techniques, genetic drivers can now be detected readily in tumors but current prognostic models for Natural-killer/T cell lymphoma (NKTCL) have yet to fully leverage on them for prognosticating patients. Here, we used next-generation sequencing to sequence 260 NKTCL tumors, and trained a genomic prognostic model (GPM) with the genomic mutations and survival data from this retrospective cohort of patients using LASSO Cox regression. The GPM is defined by the mutational status of 13 prognostic genes and is weakly correlated with the risk-features in International Prognostic Index (IPI), Prognostic Index for Natural-Killer cell lymphoma (PINK), and PINK-Epstein-Barr virus (PINK-E). Cox-proportional hazard multivariate regression also showed that the new GPM is independent and significant for both progression-free survival (PFS, HR: 3.73, 95% CI 2.07-6.73; p < .001) and overall survival (OS, HR: 5.23, 95% CI 2.57-10.65; p = .001) with known risk-features of these indices. When we assign an additional risk-score to samples, which are mutant for the GPM, the Harrell's C-indices of GPM-augmented IPI, PINK, and PINK-E improved significantly (p < .001, χ 2 test) for both PFS and OS. Thus, we report on how genomic mutational information could steer toward better prognostication of NKTCL patients. (© 2022 The Authors. American Journal of Hematology published by Wiley Periodicals LLC.) |
| References: | Aviles A. Nasal NK/T-cell lymphoma. A comparative analysis of a Mexican population with the other populations of Latin-America. Mediterran J Hematol Infect Dis 2015;7(1):e2015052. Chan JKC, Quintanilla-Martinez L, Ferry JA, Peh S-C. Extranodal NK/T-cell lymphoma, nasal type. In: Swerdlow SH, Campo E, Harris NL, et al., eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. IARC Press; 2008:285-288. Kwong YL. Natural killer-cell malignancies: diagnosis and treatment. Leukemia. 2005;19(12):2186-2194. Tse E, Kwong YL. How I treat NK/T-cell lymphomas. Blood. 2013;121(25):4997-5005. Kwong YL, Kim WS, Lim ST, et al. SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia lymphoma study group. Blood. 2012;120(15):2973-2980. Kwong YL, Chan TSY, Tan D, et al. PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase. Blood. 2017;129(17):2437-2442. Li X, Cheng Y, Zhang M, et al. Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma. J Hematol Oncol. 2018;11(1):15. Kim SJ, Lim JQ, Laurensia Y, et al. Avelumab for the treatment of relapsed or refractory extranodal NK/T-cell lymphoma: an open-label phase 2 study. Blood. 2020;136:2754-2763. Lim JQ, Huang D, Tang T, et al. Whole-genome sequencing identifies responders to Pembrolizumab in relapse/refractory natural-killer/T cell lymphoma. Leukemia. 2020;34:3413-3419. International Non-Hodgkin's Lymphoma Prognostic Factors P. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993;329(14):987-994. Kim SJ, Yoon DH, Jaccard A, et al. A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis. Lancet Oncol. 2016;17(3):389-400. Tian XP, Ma SY, Young KH, et al. A composite single-nucleotide polymorphism prediction signature for extranodal natural killer/T-cell lymphoma. Blood. 2021;138:452-463. Koo GC, Tan SY, Tang T, et al. Janus kinase 3-activating mutations identified in natural killer/T-cell lymphoma. Cancer Discov. 2012;2(7):591-597. Jiang L, Gu ZH, Yan ZX, et al. Exome sequencing identifies somatic mutations of DDX3X in natural killer/T-cell lymphoma. Nat Genet. 2015;47(9):1061-1066. Kucuk C, Jiang B, Hu X, et al. Activating mutations of STAT5B and STAT3 in lymphomas derived from gammadelta-T or NK cells. Nat Commun. 2015;6:6025. Lee S, Park HY, Kang SY, et al. Genetic alterations of JAK/STAT cascade and histone modification in extranodal NK/T-cell lymphoma nasal type. Oncotarget. 2015;6(19):17764-17776. Li Z, Xia Y, Feng LN, et al. Genetic risk of extranodal natural killer T-cell lymphoma: a genome-wide association study. Lancet Oncol. 2016;17(9):1240-1247. Lin G-W, Xu C, Chen K, et al. Genetic risk of extranodal natural killer T-cell lymphoma: a genome-wide association study in multiple populations. Lancet Oncol. 2020;21(2):306-316. Song TL, Nairismägi M-L, Laurensia Y, et al. Oncogenic activation of STAT3 pathway drives PD-L1 expression in natural killer/T cell lymphoma. Blood. 2018;35:163-164. Xiong J, Cui BW, Wang N, et al. Genomic and transcriptomic characterization of natural killer T cell lymphoma. Cancer Cell. 2020;37(3):403-419 e406. Chen S, Zhou Y, Chen Y, Gu J. Fastp: an ultra-fast all-in-one FASTQ preprocessor. Bioinformatics. 2018;34(17):i884-i890. Li H. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. Q-bioGN. 2013:arXiv:1303.3997v1301. Tarasov A, Vilella AJ, Cuppen E, Nijman IJ, Prins P. Sambamba: fast processing of NGS alignment formats. Bioinformatics. 2015;31(12):2032-2034. Okonechnikov K, Conesa A, Garcia-Alcalde F. Qualimap 2: advanced multi-sample quality control for high-throughput sequencing data. Bioinformatics. 2016;32(2):292-294. Chang X, Wang K. wANNOVAR: annotating genetic variants for personal genomes via the web. J Med Genet. 2012;49(7):433-436. Fisher RA. On the interpretation of χ 2 from contingency tables, and the calculation of P. J R Statist Soc. 1922;85(1):87. Mann HB, Whitney DR. On a test of whether one of two random variables is stochastically larger than the other. Ann Math Stat. 1947;18(1):50-60. Cramér H. Mathematical Methods of Statistics. Princeton University Press; 1946. Dinse GE, Lagakos SW. Nonparametric estimation of lifetime and disease onset distributions from incomplete observations. Biometrics. 1982;38(4):921-932. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50(3):163-170. Cox DR. Regression models and life-tables. J R Stat Soc B Methodol. 1972;34(2):187-202. Harrell FE Jr, Califf RM, Pryor DB, Lee KL, Rosati RA. Evaluating the yield of medical tests. JAMA. 1982;247(18):2543-2546. Pearson KX. On the criterion that a given system of deviations from the probable in the case of a correlated system of variables is such that it can be reasonably supposed to have arisen from random sampling. London Edinburgh Dublin Philos Mag J Sci. 2009;50(302):157-175. Shaffer MH, Dupree RS, Zhu P, et al. Ezrin and moesin function together to promote T cell activation. J Immunol. 2009;182(2):1021-1032. D'Urso CM, Wang ZG, Cao Y, Tatake R, Zeff RA, Ferrone S. Lack of HLA class I antigen expression by cultured melanoma cells FO-1 due to a defect in B2m gene expression. J Clin Invest. 1991;87(1):284-292. Martin BK, Chin K-C, Olsen JC, et al. Induction of MHC class I expression by the MHC class II Transactivator CIITA. Immunity. 1997;6(5):591-600. Van Allen EM, Golay HG, Liu Y, et al. Long-term benefit of PD-L1 blockade in lung cancer associated with JAK3 activation. Cancer Immunol Res. 2015;3(8):855-863. Nairismagi M, Gerritsen ME, Li ZM, et al. Oncogenic activation of JAK3-STAT signaling confers clinical sensitivity to PRN371, a novel selective and potent JAK3 inhibitor, in natural killer/T-cell lymphoma. Leukemia. 2018;32:1147-1156. Zaretsky JM, Garcia-Diaz A, Shin DS, et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med. 2016;375(9):819-829. Suzuki R, Yamaguchi M, Izutsu K, et al. Prospective measurement of Epstein-Barr virus-DNA in plasma and peripheral blood mononuclear cells of extranodal NK/T-cell lymphoma, nasal type. Blood. 2011;118(23):6018-6022. Ito Y, Kimura H, Maeda Y, et al. Pretreatment EBV-DNA copy number is predictive of response and toxicities to SMILE chemotherapy for extranodal NK/T-cell lymphoma, nasal type. Clin Cancer Res. 2012;18(15):4183-4190. Kim HS, Kim KH, Kim KH, et al. Whole blood Epstein-Barr virus DNA load as a diagnostic and prognostic surrogate: extranodal natural killer/T-cell lymphoma. Leuk Lymphoma. 2009;50(5):757-763. Au WY, Weisenburger DD, Intragumtornchai T, et al. Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the international peripheral T-cell lymphoma project. Blood. 2009;113(17):3931-3937. Vose J, Armitage J, Weisenburger D, International TCLP. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26(25):4124-4130. |
| تواريخ الأحداث: | Date Created: 20220621 Date Completed: 20220816 Latest Revision: 20221211 |
| رمز التحديث: | 20231215 |
| DOI: | 10.1002/ajh.26636 |
| PMID: | 35726449 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1096-8652 |
|---|---|
| DOI: | 10.1002/ajh.26636 |